Advances in the Management of Endometriosis CME Module
June 9
Advances in the Management of Endometriosis
Physicians may earn a maximum of 1.5 AMA PRA Category 1 Credits™
About this Module
This module is designed to increase clinical knowledge of the prevalence, severity and long-term effects of under and misdiagnosed endometriosis, with an emphasis on earlier, less invasive diagnoses. Physicians will come away with a clear recognition that addressing symptoms that lead to a prompt diagnosis of endometriosis is an opportunity to treat one condition without causing a preventable loss of fertility. Clinicians will recognize the need to employ more advanced diagnostic tools and better prepared to be proactive in the assessment of symptoms and solutions necessary to meet the complete needs of these patients.
Learning Objectives:
After this session, participants will be able to:
- Recognize prevalence with particular attention to health disparities in women of color
- Identify clinical characteristics, including the estrogen threshold and the role of GnRH antagonists, as well as physical and mental health consequences associated with adverse outcomes in patients with endometriosis
- Understand strategies for the early diagnostic plan without the need for surgery to reduce years of avoidable pain, emotional distress, and deterioration in the quality of life
- Develop awareness of first-line non-invasive treatment options and empiric therapy to lessen reliance on surgery with the goal of managing care to support future pregnancy
Recognize risk factors and stigmas of endometriosis throughout the lifespan
Faculty:
- Sadikah Behbehani MD, Reproductive Endocrinology and Infertility & Minimally Invasive Gynecologic Surgery at Coastal Fertility Medical Center in Irvine, CA and Associate Professor, University of California Riverside School of Medicine
- Janet Cruz MD, Minimally invasive gynecologic surgery
Continuing Education Information
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Indiana University School of Medicine and AMWA. Indiana University School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
Indiana University School of Medicine designates this enduring material activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure Summary
Indiana University School of Medicine (IUSM) policy ensures that those who have influenced the content of a CE activity (e.g. planners, faculty, authors, reviewers and others) disclose all financial relationships with any ineligible companies so that IUSM may identify and mitigate any conflicts of interest prior to the activity. All educational programs sponsored by Indiana University School of Medicine must demonstrate balance, independence, objectivity, and scientific rigor.
There are no relevant financial relationship(s) with ineligible companies for anyone who was in control of the content of this activity.
An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
This activity is supported by an educational grant from Pfizer.
